Literature DB >> 15253989

Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.

M Townsend1, D H MacIver.   

Abstract

A 63 year old man with a six year history of Parkinson's disease presented with signs of right heart failure following a knee replacement. Constrictive pericarditis was diagnosed and a radical pericardectomy performed. Six months later, the patient remained unwell with raised inflammatory markers. An inflammatory fibrotic reaction caused by cabergoline was diagnosed. He improved after cessation of cabergoline.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15253989      PMCID: PMC1768376          DOI: 10.1136/hrt.2004.036236

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

1.  Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.

Authors:  L H Ling; J E Ahlskog; T M Munger; A H Limper; J K Oh
Journal:  Mayo Clin Proc       Date:  1999-04       Impact factor: 7.616

Review 2.  [Pharmacological effects of cabergoline against parkinsonism].

Authors:  K Ichikawa; M Kojima
Journal:  Nihon Yakurigaku Zasshi       Date:  2001-06

3.  Cabergoline.

Authors:  A Colao; G Lombardi; L Annunziato
Journal:  Expert Opin Pharmacother       Date:  2000-03       Impact factor: 3.889

4.  Low dose cabergoline induced interstitial pneumonitis.

Authors:  W Frank; R Moritz; B Becke; R Pauli
Journal:  Eur Respir J       Date:  1999-10       Impact factor: 16.671

5.  Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.

Authors:  E Frans; R Dom; M Demedts
Journal:  Eur Respir J       Date:  1992-02       Impact factor: 16.671

  5 in total
  7 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

2.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 3.  Heart failure induced by non-cardiac drugs.

Authors:  Lars Slørdal; Olav Spigset
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Cabergoline in acromegaly.

Authors:  Emmanuelle Kuhn; Philippe Chanson
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 5.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS).

Authors:  Lina You; Haidong Jiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline.

Authors:  Yolanda Belmonte; Oriol de Fàbregues; Marta Marti; Christian Domingo
Journal:  Open Respir Med J       Date:  2009-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.